TREM2 and neoplasm: This synergy is exemplified by lenvatinib plus pembrolizumab, pointing toward a future paradigm of rational combinations—co-targeting tumor cells, specific immune resistance hubs (e.g., TREM2+ TAMs), and checkpoint pathways—to overcome resistance.